Product name:Blinatumomab (?蘭妥莫單抗?)

Catalog No. :?FrdE00020

MW:54100.00 Da

Description:Blinatumomab is a BiTE-class (bi-specific T-cell engagers) constructed monoclonal antibody indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).Blinatumomab is manufactured by Amgen Inc.and marketed under the brand Blincyto?.Blinatumomab was approved in December 2014 under the FDA’s accelerated approval program,which allows approval of a drug to treat a serious or life-threatening disease based on clinical data showing the drug has an effect on a surrogate endpoint reasonably likely to predict clinical benefit to patients.

Alternative names:Blinatumomab

Specificity target name;species:CD19/CD3E[Homo sapiens]

Form:?Liquid

Receptor identification:(scFv-kappa-heavy)-(scFv-heavy-kappa)

Storage:?Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 °C for frequent use. Store at -20 to -80 °C for twelve months from the date of receipt.

Purity:The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Note:?This product is for research use only,not for diagnostic or therapeutic use.